Summary: In 140 older adults diagnosed with sarcopenic obesity according to Asian Working Group for Sarcopenia criteria, TECAR (transfer energy capacitive and resistive therapy) combined with HMB (β-hydroxy-β-methylbutyrate) nutritional supplementation for 12 weeks demonstrated significant improvements in SPPB total score, Modified Barthel Index, handgrip strength, reduced body mass, and decreased BMI with confirmed synergistic effects compared to placebo for both interventions, TECAR + placebo, or sham TECAR + HMB alone, with no adverse effects reported.
| PICO | Description |
|---|---|
| Population | 140 older adults diagnosed with sarcopenic obesity according to Asian Working Group for Sarcopenia criteria, randomly assigned to four equal groups of 35 participants each. |
| Intervention | TECAR (transfer energy capacitive and resistive therapy) combined with HMB (β-hydroxy-β-methylbutyrate) nutritional supplementation for 12 weeks. |
| Comparison | Three control groups in a 2×2 factorial design: (A) placebo for both interventions, (B) TECAR + placebo supplement, and (C) sham TECAR + HMB supplementation. |
| Outcome | SPPB improved from 6.29±1.34 to 8.06±1.51. Modified Barthel Index +8.2 points. Handgrip strength +2.07 kg. Body mass -4.83 kg. BMI from 30.14 to 28.34 kg/m². Synergistic effects confirmed. No adverse effects. |
TECAR + HMB in sarcopenic obesity
RCT · 2×2 factorial · 12 weeks
TECAR plus HMB for 12 weeks produced synergistic gains in physical function and body composition, outperforming either intervention alone in older adults with sarcopenic obesity.
Clinical Context
Sarcopenic obesity represents a particularly challenging condition—the combination of excess fat mass and inadequate muscle mass creates a metabolic double jeopardy. Fat tissue promotes inflammation and insulin resistance while reduced muscle mass impairs glucose disposal and functional capacity. In older adults, sarcopenic obesity is associated with increased falls, fractures, disability, hospitalization, and mortality.
Traditional weight loss approaches risk further muscle loss in older adults, potentially worsening sarcopenia. Conversely, muscle-building interventions may not address excess adiposity. The ideal intervention would reduce fat mass while preserving or enhancing muscle.
TECAR therapy is a form of radiofrequency energy delivery that generates deep tissue heating, improving blood flow, reducing inflammation, and enhancing cellular metabolism. HMB is a metabolite of leucine with established anti-catabolic properties that may prevent muscle breakdown.
Clinical Pearls
1. Synergy Confirmed—Combination Outperforms Either Alone: The factorial design allowed confirmation of synergistic effects: neither TECAR alone nor HMB alone produced the magnitude of benefit seen with combination therapy.
2. Clinically Meaningful Physical Function Improvement: The SPPB improvement of 1.77 points exceeds the 1-point threshold for clinically meaningful change. The final score of 8.06 moves patients from “at-risk” to “normal” function category.
3. Simultaneous Weight Loss and Strength Gain: Achieving both reduced body mass (-4.83 kg) and increased handgrip strength (+2.07 kg) suggests the intervention preserved or enhanced muscle while reducing fat.
4. Non-Exercise-Based Approach May Enhance Accessibility: TECAR is a passive therapy potentially useful for those with severe mobility limitations who cannot participate in traditional exercise programs.
Practical Application
HMB supplementation (typically 3g/day in divided doses) is relatively inexpensive, safe, and can be added to existing nutritional regimens. Ensure adequate total protein intake (1.0-1.2 g/kg/day) alongside HMB supplementation.
TECAR therapy requires specialized equipment and trained practitioners. Consider referral to facilities with TECAR capability. Use functional assessments like the SPPB and handgrip dynamometry to monitor progress.
Broader Evidence Context
HMB has moderate evidence for muscle preservation in older adults. TECAR therapy has primarily been studied for musculoskeletal pain and sports rehabilitation—its application in metabolic conditions like sarcopenic obesity is novel. The combination approach aligns with growing recognition that multimodal interventions may be more effective than single interventions for complex conditions.
Study Limitations
Study conducted in Asian population; generalizability to other populations uncertain. TECAR equipment and protocols are not standardized. Twelve-week duration doesn’t establish long-term durability. Body composition (fat vs lean mass changes) wasn’t specifically reported with imaging.
Bottom Line
Combining TECAR therapy with HMB supplementation produces synergistic improvements in physical function, strength, and body weight in older adults with sarcopenic obesity, exceeding benefits of either intervention alone. Consider this combination approach for patients with this challenging condition.
Source: Wang R, et al. “Efficacy of Transfer Energy Capacitive and Resistive Therapy Combined With beta-Hydroxy-beta-Methylbutyrate Nutritional Supplementation in Older Adults With Sarcopenic Obesity.” Read article.